Co-stimulation Blockade, Hemophilic Inhibitors and Tolerance

Jiahua Qian; Evgueni Saenko; David Scott

doi:10.1055/s-0037-1616732

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2001; 86(06): 1343-1344
DOI: 10.1055/s-0037-1616732

Commentary

Schattauer GmbH

Co-stimulation Blockade, Hemophilic Inhibitors and Tolerance

Authors

Jiahua Qian

¹Departments of Immunology
Evgueni Saenko

²Biochemistry, Holland Laboratory of the American Red Cross, Rockville, MD, USA
David Scott

¹Departments of Immunology

Abstract

Full Text

References

References
1 Qian J, Collins M, Sharpe AH, Hoyer LW. Prevention and treatment of factor VIII inhibitors in murine hemophilia A. Blood 2000; 95: 1324-9.
2 Noelle RJ, Ledbetter JA, Aruffo A. CD40 and its ligand, an essential ligand-receptor pair for thymus-dependent B-cell activation. Immunol Today 1992; 13: 431-3.
3 Van den Eertwegh AJ, Noelle RJ, Roy M, Shepherd DM, Aruffo A, Ledbetter JA, Boersma WJ, Claassen E. In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. I. In vivo expression of CD40 ligand, cytokines, and antibody production delineates sites of cognate T-B cell interactions. J Exp Med 1993; 178: 1555-65.
4 Han S, Hathcock K, Zheng B, Kepler TB, Hodes R, Kelsoe G. Cellular interaction in germinal centers. Roles of CD40 ligand and B7-2 in established germinal centers. J Immunol 1995; 155: 556-67.
5 Foy TM, Laman JD, Ledbetter JA, Aruffo A, Claassen E, Noelle RJ. gp39-CD40 interactions are essential for germinal center formation and the development of B cell memory. J Exp Med 1994; 180: 157-63.
6 Noelle RJ, Mackey M, Foy T, Buhlmann J, Burns C. CD40 and its ligand in autoimmunity. Ann N Y Acad Sci 1997; 815: 384-91.
7 Waldmann H. Transplantation tolerance – where do we stand?. Nat Med 1999; 5: 1245-8.
8 Ewenstein BM, Hoots WK, Lusher JM, DiMichele D, White 2nd GC, Adelman B, Nadeau K. Inhibition of CD40 ligand (CD154) in the treatment of factor VIII inhibitors. Haematologica 2000; 85 10 Suppl 35-9.
9 Kirk AD, Harlan DM, Armstrong NN, Davis TA, Dong Y, Gray GS, Hong X, Thomas D, Fechner Jr JH, Knechtle SJ. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci USA 1997; 94: 8789-94.
10 Kirk AD, Burkly LC, Batty DS, Baumgartner RE, Berning JD, Buchanan K, Fechner Jr JH, Germond RL, Kampen RL, Patterson NB. et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med 1999; 5: 686-93.
11 Qian J, Burkly LC, Smith EP, Ferrant JL, Hoyer LW, Scott DW, Haudenschild CC. Role of CD154 in the secondary immune response: the reduction of pre-existing splenic germinal centers and anti-factor VIII inhibitor titer. Eur J Immunol 2000; 30: 2548-54.
12 Rossi G, Sarkar J, Scandella D. Long-term induction of immune tolerance after blockade of CD40-CD40L interaction in a mouse model of hemophilia A. Blood 2001; 97: 2750-7.
13 Jahreis A, Homann D, Wolfe T, Hughe A, Coon B, von Stipendonk M, Schonberber S, von Harath M. Blockade of CD40L during activation of the auto-aggressive response prevent autoimmune diabetes by inducing regulatory Cd11c antigen presenting cells. Abstract, 11th International Congress of Immunology. 2001, W 3.6.